Vardenafil in Erectile Dysfunction: The Evidence of Its Therapeutic Value

Size: px
Start display at page:

Download "Vardenafil in Erectile Dysfunction: The Evidence of Its Therapeutic Value"

Transcription

1 Clinical Medicine Insights: Therapeutics Review pen Access Full open access to this and thousands of other papers at Vardenafil in Erectile Dysfunction: The Evidence of Its Therapeutic Value Kevin R. Rice and Robert C. Dean Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307, USA. Corresponding author The opinions and assertions contained herein are the private views of the authors and are not to be considered as reflecting views of the U.S. Army or the Department of Defense. Abstract: Erectile dysfunction (ED) is a condition that affects approximately 18 million American men. Phosphodiesterase-5 inhibitors (PDE5i s) have revolutionized the treatment of erectile dysfunction by providing the first highly-effective oral medication. Vardenafil is one of 3 PDE5i s commercially available for the treatment of ED in the United States. It has demonstrated therapeutic efficacy in the management of uncomplicated ED as well as more refractory cases associated with diabetes and surgery for prostate cancer. The physiology, pharmacokinetics, pharmacodynamics, and primary literature evaluating vardenafil are reviewed. Keywords: erectile dysfunction, phosphodiesterase 5 inhibitors, impotence, vardenafil Clinical Medicine Insights: Therapeutics 2010: doi: /CMT.S3787 This article is available from the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. The authors grant exclusive rights to all commercial reproduction and distribution to Libertas Academica. Commercial reproduction and distribution rights are reserved by Libertas Academica. No unauthorised commercial use permitted without express consent of Libertas Academica. Contact tom.hill@la-press.com for further information. Clinical Medicine Insights: Therapeutics 2010:2 965

2 Rice and Dean Introduction Erectile dysfunction (ED) is a condition that affects approximately 18 million American men. 1 The incidence appears to be increasing, although this is likely related to increased public awareness and self-reporting. The increased awareness that has taken place over the last decade is due in no small part to the discovery of the therapeutic efficacy of phosphodiesterase-5 inhibitors (PDE5i s) in treating ED as well as the marketing campaigns of the 3 formulations that are commercially-available in the United States. PDE5i s have revolutionized the treatment of erectile dysfunction. Whereas ED was traditionally a condition managed by specialists, the introduction of PDE5i s has resulted in management of ED in the primary care setting. PDE5i s provide arguably the most physiologic erection of the available treatments for ED. PDE5i s have traditionally been prescribed and studied as on-demand medications for the treatment of ED. However, with the recent exploration of once daily maintenance therapy as well as postradical prostatectomy penile rehabilitation, there is potential for new ways to apply these medications to the management of ED. Physiology of Penile Erection In the flaccid state, there is very little blood flow to the corpora cavernosa. The hemodynamics of the penis in this setting are the result of baseline sympathetic tone. This sympathetic input maintains vasoconstriction of the cavernosal arteries as well as contraction of the cavernosal smooth muscles surrounding the lacunar spaces. The flaccid penis is smaller in this state, because this sympathetic tone minimizes cavernosal arterial inflow, corporal cavernosal volume, and ability of the corpora to trap blood. The small amount of blood that enters the corpora cavernosa exits through venules that pierce the tunica albuginea of the penile shaft. This blood then drains through the venous systems of the penis. The physiologic process of penile erection involves both cavernosal filling and trapping of blood. Upon sexual stimulation, cholinergic end neurons of the parasympathetic neurons arising from spinal segments S2-4 produce acetylcholine which acts through the inositol triphosphate pathway to increase the conversion of l-arginine to nitric oxide (N) by endothelial nitric oxide synthase (ens). This results in arteriolar dilation and increased cavernosal blood flow. Simultaneously, the nitrergic end neurons of parasympathetic nerves S2-4 located in the cavernosal tissue release N. N is produced by the cleavage of l-arginine by neuronal nitric oxide synthase (nns). Production of N results in the conversion of GTP to cgmp by guanylate cyclase. cgmp interacts with protein Kinase G resulting in calcium shifts into the sarcoplasmic reticulum and relaxation of the carvernosal smooth muscles. The result of these processes is a 20 to 40-fold increase in cavernosal blood flow. The penis then enlarges in both length and girth until the tunica albuginea surrounding the corpora cavernosa reaches its maximum capacity for stretch. nce this occurs, the intracavernosal pressure increases. This increase in intracavernosal pressure compresses the venules against the underside of the tunica albuginea, preventing venous outflow of intracavernosal blood and providing the mechanism by which blood is trapped in the corpora cavernosa of the erect penis. Mechanism of Phosphodiesterase-5 Inhibitors Phospodiesterases (PDEs) are intracellular enzymes that regulate breakdown of cyclic nucleotides. 2 PDE5 is one of eleven mammalian PDE families. Inhibition of PDE5 prevents the breakdown of cgmp, which promotes calcium sequestration into the sarcoplasmic reticulum of cavernosal smooth muscle cells. This results in potentiated smooth muscle relaxation and cavernosal engorgement (Fig. 2). 3 Vardenafil (Levitra ) was the second PDE5i to receive FDA approval for the treatment of ED in the United States (Fig. 1). Vardenafil is the most potent of the commercially-available PDE5i s, although this has not been demonstrated to result in a clinical advantage over other PDE5i s. The IC 50 is the in vitro N N Figure 1. Chemical structure of vardenafil. S HN N N N 966 Clinical Medicine Insights: Therapeutics 2010:2

3 Vardenafil Corpus cavernosum Cell Membrane ERECTIN Guanylate Cyclase GTP GMP cgmp Smooth Muscle Relaxation HN S N N N N N VARDENAFIL Figure 2. Mechanism of vardenafil. concentratration at which 50% of phosphodiesterase 5 is inhibited. The IC 50 for vardenfil is 0.1 to 0.7 nm. The IC 50 of sildenafil is 3.9 nm. 4 The IC 50 of tadalafil is 0.94 nm. 5 The maximal plasma concentration (Cmax) for vardenafil 20 mg 20.9 ng/ml vs. 327 and 378 ng/ml for sildenafil 100 mg and tadalafil 20 mg, respectively. The time to reach Cmax for vardenafil is similar to sildenafil at 0.7 to 0.9 hours and considerably shorter than that of tadalafil (2 hours). The half life of vardenafil is similar to sildenadfil at 4 to 5 hours, but shorter than the half life of tadalafil, which is 17.5 hours. 5,6 As with sildenfail, consumptions of a high fat meal prior to taking vardenafil prolongs the time to reach Cmax. Unlike sildenafil, consumption of a high-fat meal does not alter is relative bioavailability. The delay in reaching Cmax has not been observed in low to moderate fat meals. 7 Tadalafil s absorption and bioavailability does not appear to be altered by high-fat meals. 8 With regard to selectivity, the affinity of vardenafil for PDE5 versus PDE6 is.15:1. This is higher than that of sildenafil (10:1) but lower than that of tadalafil (.700:1). Crossreactivity with PDE6 is responsible for the blurred vision that some patients may experience when taking PDE5i s. Indeed, comparative evaluation of side effects by patients taking once of the 3 PDE5i s has demonstrated increased blurred vision in patients taking sildenafil versus the other two PDE5i s. 9 Vardenafil s affinity for PDE5 vs. PDE11 is.300:1, which is less than that of Sildenafil (.700:1), but more than that of tadalafil (20 to 40:1). This may explain why there is a higher incidence of musculoskeletal pain in patients taking tadalafil. 9 Clinical Efficacy of Vardenafil In 2001, Klotz et al performed a pharmacokinetic and pharmacodynamic study of vardenafil in 21 men with ED. The study was a prospective randomized, double-blind, placebo-controlled crossover trial. utcomes were measured with a RigiScan. A Rigiscan is a device that consists of two cuffs worn at the base and tip of the penis. These cuffs measure radial penile rigidity at these two locations. This is then expressed as percentage of total rigidity (100%). The subjects in this trial wore the device 0.5 hour prior to dosing and then 2.5 hours after dosing. The subjects watched sexually explicit videos and RigiScan measurements were taken. The primary endpoint of the study was the length of time that penile rigidity was.60%. Vardenafil was evaluated at single doses of 10 and 20 mg. Compared to placebo, subjects receiving 10 mg demonstrated an increase in duration of.60% Clinical Medicine Insights: Therapeutics 2010:2 967

4 Rice and Dean rigidity of 24.4 and 24.8 minutes at the base and tip of the penis, respectively. Subjects receiving 20 mg vardenafil demonstrated an increase in duration of 37.2 and 28.7 minutes at the base and tip, respectively. With regard to pharmacokinetics, vardenadil demonstrated a T max (time from administration to maximal plasma concentration) of 0.7 to 0.9 hours and a serum half life of 4.2 hours. 10 This study confirmed the therapeutic efficacy and specific pharmacokinetics of vardenafil. Porst et al performed the first at home evaluation of vardenafil in 601 men. This was a multicenter, randomized, double-blind, placebo-controlled trial evaluating vardenafil at 5, 10, and 20 mg doses over a 12-week treatment period. Primary endpoints were answers to questions 3 (When you attempted intercourse, how often were you able to penetrate your partner?) and 4 (During intercourse, how often were you able to maintain your erection after you entered your partner?) of the International Index of Erectile Function (IIEF). The IIEF is a validated 15-item questionnaire designed to measure the degree of erectile dysfunction. Each question is answered on a 0 5 scale, with a score 5 indicating better function. All three doses of vardenafil demonstrated a statistically significant increase in positive responses to questions 3 and 4. Additionally, patients receiving vardenafil demonstrated statistically significant increases in all domain scores of the IIEF. Eighty percent of men receiving the 20 mg dose responded positively to the global assessment question (Has the treatment you have been taking for the last 4 weeks improved your erections?) compared to 30% for men receiving placebo. Treatment-emergent adverse events were dose-related and included headache (7% 15%), flushing (10% 11%), dyspepsia (1% 7%), and rhinitis (3% 7%). 11 This was the first study to report the efficacy of vardenafil in enabling men with ED to engage in successful sexual intercourse as determined utilizing a validated instrument. In 2003, Hellstrom et al published a phase III, multi-center, randomized, double-blind, placebocontrolled, four-arm, parallel-group, fixed dose comparison study. Eight hundred and five patients were treated with of vardenafil 5 mg, 10 mg, 20 mg, or placebo for 26 weeks. Efficacy was determined through utilization of several metrics. Subjects were asked to answer IIEF questions 1 5 and 15 (IIEF-ED) after 12 weeks of treatment. They were also asked to answer the sexual encounter profile question 2 (SEP2) Were you able to insert your penis into your partner s vagina? as well as the sexual encounter profile question 3 (SEP3) Did your erection last long enough for you to have successful intercourse? Secondary outcomes included answers to the above questions at 26 weeks as well as a global assessment question. All vardenafil treatment arms demonstrated statistically significant improvements in primary outcomes. Mean EF domain score improved from 12.5 to 18.4, from 13.4 to 20.6, and from 12.8 to 21.4 from baseline to 12 week follow-up for vardenafil 5, 10, and 20 mg treatment groups, respectively (P, vs. placebo). The placebo arm did not demonstrate a significant change in EF domain score over the study period. The mean successful penetration rate improved from 42.8 to 65.5%, 45.4 to 75.5%, and 40.9 to 80.5% from baseline to 12 week follow-up in the vardenafil 5, 10, and 20 mg treatment groups (P, vs. placebo). The mean ability to maintain an erection for successful intercourse improved from 14.0 to 50.6%, 14.6 to 64.5%, and 14.7 to 64.5% in the vardenafil 5, 10, and 20 mg treatment groups, respectively (P, ). These statistically significant improvements were maintained at 26 week follow-up. 12 This study confirmed vardenafil s efficacy and safety in treating ED. Erectile Dysfunction and Comorbid Conditions The presence of ED has been suggested to be associated with an increased risk of future cardiac events. In two large scale analyses, the presence of ED was found to be a harbinger for future cardiac events. 13,14 This is thought to be due to the common vascular pathology contributing to these two conditions. This has led to the investigation of the effect of cardiovascular risk factors, comorbid conditions, medications, and their relationship to the management of ED with PDE5i s. ED develops in greater than 50% of patients within 10 years of being diagnosed with diabetes. In the Massachusetts Male Aging Study, the age-adjusted probability of developing ED was three times high in patients with diabetes compared to those without this condition. 15 In diabetic patients, ED is often associated with peripheral vascular disease and diabetic neuropathy. 16,17 Reported success rates of PDE5i s in treating ED in diabetic patients have been lower 968 Clinical Medicine Insights: Therapeutics 2010:2

5 Vardenafil than those reported evaluating their use in the general population. 18 Goldstein et al examined the efficacy of vardenafil in treating ED in diabetic patients in a phase III multi-center prospective randomized double-blind placebo-controlled trial published in In this trial 452 diabetic males were randomized to receive placebo, vardenafil 10 mg, or vardenafil 20 mg for 12 weeks. Primary outcomes were improvement in the IIEF-EF and answers to SEP2 and SEP3 questions. The mean improvement in the IIEF erectile function domain was 5.9 and 7.8 for vardenafil 10 and 20 mg (P = 0.03), respectively compared to 1.4 for placebo (P, ). The percentage of subjects self-reporting successful vaginal penetration was 36, 61, and 64% for placebo, vardenafil 10 mg, and 20 mg respectively (P, vs. placebo). The self-reported ability to maintain an erection until the end of intercourse was 23, 49, and 54% in the placebo, vardenafil 10 mg, and 20 mg groups, respectively (P, ). 19 This was the first study demonstrating the efficacy of vardenafil in treating diabetic males. Subsequent studies have confirmed vardenafil s efficacy in treating ED in diabetic patients with success rates similar to those reported for sildenafil in treating this patient population. 20,21 In 2006, Ziegler et al evaluated the efficacy of vardenafil in treating ED in men with type 1 diabetes mellitus. In this multicenter, double-blind, placebo-controlled trial, 302 PDE5i-naïve men were randomized to receive placebo or flexible dose vardenafil. Primary outcomes were answers to SEP2 and SEP3. Secondary outcomes were IIEF scores. Patients receiving vardenafil demonstrated significant improvements in SEP2 and SEP3 regardless of level of glycemic control (P, ). 20 The percentage of men responding positively to SEP2 and SEP3 was 71 and 50% after 12 weeks of treatment. These numbers are similar to that reported by Goldstein et al in their study on the use of vardenafil in diabetic patients, 19 but lower than those reported in the general population of men with ED. This seems to indicate that diabetic patients tend to have more refractory ED than patients without diabetes, but that this may not be a function of level of glycemic control. The efficacy of vardenafil in the treatment of men with dyslipidemia was demonstrated by Miner et al in In this multicenter, randomized, doubleblind, placebo-controlled study of 712 men who had been on statin therapy for at least 3 months were given flexible dose vardenafil or placebo. Significant improvements in IIEF-EF, SEP2, and SEP3 were demonstrated. In a follow-up randomized, doubleblind placebo- controlled, parallel group study, the same investigators evaluated the relationship between severity of dysplipidemia and efficacy of flexible dose vardenafil. nce again, outcomes included IIEF-EF, SEP2, and SEP3. In addition, a stopwatch-assessed duration of erection was performed. Subgroup analysis was performed based low density lipoprotein cholesterol (LDL-C) levels, total cholesterol to high density lipoprotein cholesterol ratio (TC/HDL-C), and the presence or absence of the metabolic syndrome. nce again, vardenafil treatment was associated with a significant improvement in all outcome measures regardless of subgrouping. Interestingly, patients with higher LDL-C experienced a greater increase in IIEF-EF despite similar baseline scores (P = 0.033). However, neither TC/HDL-C nor the presence of metabolic syndrome were associated with significant changes in IIEF-EF scores. Response to SEP2 did not differ significantly between subgroups. Response to SEP3 followed a similar pattern to the IIEF-EF score, with high LDL-C being associated with a significantly increased positive response rate (P = 0.019). The mean duration of erection sufficient for penetration was significantly longer in the patients of a TC/HDL-C greater than or equal to 3.5 (P = 0.028). 23 While the findings of this study fail to demonstrate a clear pattern of therapeutic efficacy among subgroups, all significant associations seem to be paradoxical. This may be explained by the fact that all patients in this study were on stable statin therapy. Thus, the lipoprotein levels used to stratify patients do not necessarily reflect baseline severity of dyslipidemia. Additionally, given the flexible-dose study design, patients with more severe dyslipidemia may have been receiving higher doses of vardenafil. Furthermore, no information was available regarding comorbid medical conditions as well as concomitant medications, all of which can have significant effects on erectile and sexual function. Eardley et al performed a retrospective analysis of 13 randomized, double-blind, placebo-controlled trials investigating the use of vardenafil in patients with diabetes mellitus, hypertension, dyslipidemia, and/or the metabolic syndrome. utcome measures were change in IIEF-EF score and answers to SEP2 and Clinical Medicine Insights: Therapeutics 2010:2 969

6 Rice and Dean SEP3 questions. The investigators found significant improvement in all outcome measures regardless of underlying medical condition(s). Interestingly, the authors found that the level of glycemic control as well concomitant use of medications for the treatment of diabetes mellitus, hypertension, and dyslipidemia had no significant effect on efficacy of vardenafil. 24 Antihypertensive medications in particular have been demonstrated to adversely affect erectile function. 25 Given that sexual side effects can have a negative effect on patient compliance with these medications, the ability to minimize these effects can improve compliance and potentially prevent untoward cardiac events. Indeed, McLaughlin et al has demonstrated that prescribing sildenafil can improve patient compliance with antihypertensives, oral hypoglycemics, and antidepressants. 26 Sexual dysfunction, to include ED, is known to occur with significant frequency in patients with schizophrenia. 27 Whether ED in these patients is a consequence of symptoms of schizophrenia or antipsychotic medications is unclear. 28 In 2006, Gopalakrishnan et al performed a randomized, double-blind, placebo-controlled trial that demonstrated sildenafil to significantly improve erectile function in men with antipsychotic-induced ED. 29 Mitsonis et al performed a 12-week, open-label study of the efficacy of flexible-dose vardenafil in the treatment of ED in patients with schizophrenia. The IIEF was used to measure sexual function outcomes. A schizophrenia-specific Quality of Life Scale (QLS) 30 was administered to evaluate the effect of vardenafil on the patients overall quality of life. Vardenafil resulted in a statistically significant improvement in all IIEF domains as well as in the QLS when compared to baseline. 31 The strength of these results is weakened by the study s small size and lack of a control group. However, the significant improvement in overall quality of life as well as in all domains of the IIEF experienced by patients after being treated with vardenafil highlights the profound effect that PDE5i s can have on patients suffering from schizophrenia. Further large scale placebo-controlled studies are needed to confirm these findings. Erectile dysfunction and lower urinary tract symptoms related to benign prostatic enlargement are both conditions that commonly affect the aging male patient. Concomittant management of these conditions has raised concern as PDE5i s and α-blockers can both result in hypotension. Simultaneous administration of vardenafil and α-blockers to healthy volunteers resulted in clinically significant decreases in blood pressure. Thus, the simultaneous use of alpha blockers and vardenafil was initially contraindicated. 32 Subsequent studies demonstrated that this effect was mitigated by separating the dosing of these two medications by at least 6 hours. Additionally, the use of the α1a receptor blocker tamsulosin further reduced the incidence of hypotension. 33 Thus, the contraindication on simultaneous administration was lifted by the FDA. It is now recommended that patients should be stable on α-blocker therapy before being started on the lowest vardenafil dose that is clinically effective. 34 Comparative Studies In a prospective, randomized, double-blind, crossover study performed in 2006, investigators compared vardenafil and sildenafil in treating patients with diabetes mellitus, hypertension, and/or hyperlipidemia. A total of 931 men were included in the intent to treat population. The two drugs were assessed for patient preference, efficacy, and adverse events. With regard to preference, 683 (73.4%) of patients responded to the question. Vardenafil was preferred by 38.9% of patients, sildenafil by 34.5% of patients, and 26.6% of patients had no preference. This difference was not statistically significant. The IIEF-EF, SEP2, SEP3, and GAQ were used to evaluate efficacy, and responses to the treatment satisfaction scale (TSS). Vardenafil demonstrated statistical superiority in the included IIEF-EF, SEP2, SEP3, GAQ, and 12 of 19 TSS items. No significant differences were noted for the remaining 7 TSS items. Incidence of adverse events was low and similar between vardenadil and sildenafil. This was the first study to suggest that vardenafil may have increased therapeutic efficacy when compared to sildenafil. However, it should be noted that nominal significance does not necessarily translate into clinical significance. Indeed, no statistical difference in patient preference was demonstrated. 35 Further similarly-designed studies will be necessary in order to compare the efficacy of all 3 PDE5i s. Additionally, subgroup analysis with regard to medical comorbidities may help to identify specific therapeutic niches for each medication. 970 Clinical Medicine Insights: Therapeutics 2010:2

7 Vardenafil In 2009 Jannini et al reported on an open-label, randomized, multicenter crossover study comparing sildenafil 50 mg, sildenafil 100 mg, tadalafil 20 mg, and vardenafil 20 mg in the treatment of ED. 36 f note, data from the crossover portion of this study were not presented in this publication. These data will likely be published in subsequent manuscripts. ne hundred thirty-four men were randomized to one of the four study arms. Primary outcome was efficacy as determined by IIEF-ED scores after 8 weeks of treatment. Secondary outcomes were penile hemodynamic parameters as determined by penile duplex after intracavernosal injection of alprostadil. f note, hemodynamic studies were not performed during the therapeutic window for the assigned PDE5i. No significant differences in primary outcomes were demonstrated between any of the 4 study groups. Sildenafil 50 and 100 mg were both associated with improvements in cavernosal peak systolic velocity when compared to baseline. nly patients receiving sildenafil 100 mg demonstrated a significant improvement in resistive index when compared to baseline. The clinical implications of these hemodynamic findings are not clear. Additionally, the findings of this study are weakned by the open label nature and a high attrition rate (25%). Vardenafil in the Treatment of Postprostatectomy Erectile Dysfunction ED can occur in over one third of patients undergoing radical prostatectomy for the treatment of prostate cancer. The cavernosal nerves course posterolateral to the prostate bilaterally before piercing the pelvic diaphragm and entering the corpora cavernosa. These nerves are responsible for releasing N in response to sexual arousal leading to cavernosal engorgement as described above. The cavernosal nerves are vulnerable to injury during the posterolateral dissection performed during radical prostatectomy. Nerve-sparing techniques utilized in open, laparoscopic, and robotic-assisted prostatectomies are aimed at minimizing permanent ED. However, even patients who go on to experience a full recovery of erectile function tend to experience a variable period of severe ED following surgery. In these cases, the etiology of this transient ED is thought to be related to surgery- induced neuropraxia rather than complete transection. In 2003, Brock et al published the first study examining the efficacy of vardenafil in treating postprostatectomy ED. This was a randomized, placebocontrolled, double-blind, fixed-dose, parallel group study examining the efficacy of vardenafil in restoring erectile function in men with postprostatectomy ED having undergone either bilateral or unilateral nervesparing radical retropubic prostatectomy. Efficacy was assessed using a GAQ. 65.2, 59.4, and 12.5% of patients receiving vardenafil 20 mg, 10 mg, and placebo reported improvement in erections, respectively. The strongest predictor of therapeutic efficacy was pretreatment ED rather than whether nerve sparing was unilateral or bilateral. 37 While this study clearly demonstrates improved erections in the patients having received vardenafil, findings are weakened by the lack of a validated instrument for assessing erectile function. In recent years, several investigators have evaluated the role for penile rehabilitation in the treatment of postprostatectomy ED. This practice of penile rehabilitation is based on muscular rehabilitation programs that have proven beneficial in treating striated muscle denervation injuries. The regular oxygenation of the corpora cavernosa that occurs during sexual arousal as well as during nocturnal penile tumescence (NPT) may serve to maintain healthy corporal tissue. Corporeal oxygen tension has been demonstrated to increase from mmhg in the flaccid state to mmhg during erection. 38 This oxygen may be necessary for the efficient synthesis of N. Furthermore, the results of several animal models have demonstrated that prolonged lack of cavernosal engorgement with its associated relative hypoxia may be associated with elevated levels of TGF-β resulting in corporeal fibrosis. 39 Thus, in theory, early intervention may prevent cavernosal smooth muscle atrophy and apoptosis as well as corporal fibrosis. This is thought to lead to a corporal veno-occlusive disorder (CVD) where cavernosal arterial inflow is intact, but the emissary veins are never completely compressed against the tunica of the corpora cavernosa resulting in continuous venous leak. Montorsi et al described the first prospective, randomized trial evaluating the therapeutic efficacy of restoring erections in the early postprostatectomy period. In this study 30 men having undergone nerve-sparing radical retropubic prostatectomy were Clinical Medicine Insights: Therapeutics 2010:2 971

8 Rice and Dean randomized to receive intracavernosal alprostadil three times a week for twelve weeks or to be observed over the same time period. Patients were then evaluated six months after surgery with a detailed sexual history, penile Doppler examination, and RigiScan. Twelve of the 15 (80%) patients in the treatment arm completed the study. f these patients, 8 of 12 (67%) reported recovery of spontaneous erections sufficient for vaginal penetration compared to 2 of 15 (20%) in the control arm (P, 0.01). Ten of the 12 (83%) patients in the treatment group, including all complete responders and 2 partial responders, had normal penile hemodynamics, while 2 of the partial responders demonstrated CVD on Doppler examination. Within the control group, all 3 men with recovery of spontaneous erections and 2 of the failures demonstrated normal penile hemodynamics. However, 8 (67%) of the failures in this group demonstrated CVD and 2 demonstrated arterial insufficiency. Thus, there was a 33% incidence of normal penile hemodynamics, a 14% incidence of arterial insufficiency, and a 53% incidence of CVD in the control group. This study demonstrated both clinical and radiologic evidence of a potential benefit of early restoration of erections after prostatectomy. The striking difference in the incidence of CVD between the treatment and control groups (17 vs. 53%, respectively) would seem to indicate that this is the penile vascular pathology prevented by early restoration of erections. 40 The impressive results of this study are tempered by its small numbers as well as the 20% attrition rate in the treatment group. To date, these results have not been replicated in a large prospective study. The role for PDE5i s in the treatment of postprostatectomy ED has been well-established. However, their utilization in the setting of postprostatectomy penile rehab is more controversial. The main argument against their ability to restore spontaneous erections in these patients is that PDE5i s require the production of N in order to have their effect. Thus, they would not be expected to be particularly effective in patients who have ED resulting from postsurgical cavernosal neuropraxia or injury. However, the results of several animal models as well as clinical studies have offered potential mechanisms for the efficacy of PDE5i s in this setting. In a study performed by Ferrini et al the administration of vardenafil to rats after cavernosal neurotomy reduced the incidence of smooth muscle loss and cavernosal fibrosis. This is thought to be due to an increase in intracellular cgmp in smooth muscle cells. 41 In another animal model study, administration of sildenafil to rats within 24 hours of stroke was associated with increased neurogenesis and decreased neurologic deficits. This study suggests that PDE5i s may possess neuroprotective properties. 42 Additionally, there is evidence PDE5i s can promote endothelial health as demonstrated by an increase in the number of circulating endothelial progenitor cells in humans as well as increasing cavernous endothelial cells in diabetic rats. 43,44 Much of the initial interest regarding the use of PDE5i s in postprostatectomy penile rehabilitation was in response to a study by Padma-Nathan et al presented at the 2003 American Urological Association (AUA) Annual Meeting. In this study, 76 men with normal preoperative erectile function (defined as a combined score of 8 when answering SEP2 and SEP3 as well as normal NPT testing by RigiScan) having undergone radical retropubic prostatectomy with bilateral nerve-sparing were randomized to receive nightly sildenafil 50 mg (n = 23), sildenafil 100 mg (n = 28), or placebo (n = 25) starting 4 weeks postoperatively and continuing for 36 weeks. The patients were then reassessed 8 weeks after the treatment period (postop week 48) with SEP2, SEP3, and their response to the following question: ver the past 4 weeks, have your erections been good enough for satisfactory sexual activity? Fourteen of the fifty-one (27%) patients who received nightly sildenafil compared to 1 of 25 (4%) patients in the placebo group reported the return of spontaneous erectile function (P = ). 45 The authors propose that the sevenfold increase in the incidence of spontaneous erections when compared to the placebo group offers definitive evidence of the efficacy of nightly sildenafil. However, the rates of erectile function in both groups are far lower than those reported on prostate cancer outcomes studies. Thus, the applicability of these data is questionable. In 2008, Montorsi et al reported on a large multicenter, prospective, randomized, double-blind, placebo-controlled, crossover trial evaluated the efficacy of nightly versus on-demand vardenafil in the treatment of postprostatectomy erectile dysfunction. 972 Clinical Medicine Insights: Therapeutics 2010:2

9 Vardenafil Patients with IIEF-EF score 22 (%) * Placebo Vardenafil nightly Vardenafil on demand 0 n = End of double-blind treatment period End of 2-mo single-blind washout period End of open-label on-demand period Figure 3. Percentage of patients with IIEF-EF score $22 at the end of double-blind, single-blind washout, and open label on demand periods. Reproduced with permission from Elsevier. In this study 668 men with normal preoperative erectile function scheduled to undergo bilateral nerve-sparing radical prostatectomy were randomized receive vardenafil 10 mg nightly with placebo on-demand, nightly placebo with flexible dose vardenafil on-demand, or placebo nightly and on-demand for 9 months. Following the initial 9 months, there was a 2 month washout period with placebo. Finally, patients entered a 2-month period open-label vardenafil on demand. This study was designed to both evaluate the efficacy of vardenafil on demand versus nightly administration in restoring function erections. Additionally, the washout period followed by an open label period was designed to determine whether early administration nightly or on-demand vardenafil could improve long term erectile function rates. Four hundred twenty-three men completed the study. As depicted graphically in Figure 3, at the end of the initial 9-month double-blind treatment period, the proportion of patients reporting an IIEF score of $22 was 24.8%, 32.0%, 48.2% in those receiving placebo, nightly vardenafil and vardenafil on demand, respectively (P, for vardenafil on demand vs. placebo). Additionally, the difference in patients reporting an IIEF score of $22 was statistically higher in the on-demand versus nightly vardenafil groups at several points during the double-blind period (P = ). No significant difference in the proportion of men reporting an IIEF Score of $22 was appreciated between the three groups at the end of the single-blind washout or open label on demand periods of the study. 46 Thus, this study provides powerful evidence against the efficacy of vardenafil (and other PDE5i s) in restoring spontaneous erections in men with initial postprostatectomy ED. Conclusion ver a decade after initial FDA approval, PDE5is remain the first line treatment for erectile dysfunction. This is due to excellent efficacy in the setting of relatively few adverse effects. Vardenafil has been associated with excellent success in treating ED in the setting of multiple medical and surgical comorbidities. The superior potency and selectivity for PDE5 when compared to the other two commercially available PDE5i s has not been demonstrated to translate into clinical superiority. However, further comparative studies are necessary. Disclosure This manuscript has been read and approved by all authors. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. Dr. Dean has received a research grant from Pfizer Co. Dr. Rice and the peer reviewers of this paper report no conflicts of interest. The authors confirm that they have permission to reproduce any copyrighted material. Clinical Medicine Insights: Therapeutics 2010:2 973

10 Rice and Dean References 1. Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med Jan 23;166(2): Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev ct;75(4): Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am Nov;32(4):379 95, v. 4. Wallis RM. The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5. Nippon Yakurigaku Zasshi ct; 114 Suppl 1:22P Curran M, Keating G. Tadalafil. Drugs. 2003;63(20): ; discussion Bischoff E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res Jun ;16 Suppl 1: S Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of highfat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol Mar;43(3): Brock GB. Tadalafil: a new agent for erectile dysfunction. Can J Urol Feb;10 Suppl 1: Taylor J, Baldo B, Storey A, Cartledge J, Eardley I. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int May;103(10): Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol Feb;19(1): Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res Aug;13(4): Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl Nov Dec;23(6): Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA Dec 21;294(23): Inman BA, Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc Feb;84(2): Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol Jan;151(1): Saenz de Tejada I, Goldstein I. Diabetic penile neuropathy. Urol Clin North Am Feb;15(1): Braunstein GD. Impotence in diabetic men. Mt Sinai J Med Mar;54(3): Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA Feb 3;281(5): Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care Mar;26(3): Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med Sep;3(5): Nagao K, Kobayashi H, Fujikawa K, et al. Vardenafil allows successful intercourse initiated rapidly after dosing in Japanese patients with diabetes mellitus and erectile dysfunction. J Sex Med ct;6(10): Miner M, Gilderman L, Bailen J, et al. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med Jun;5(6): Miner MM, Barnes A, Janning S. Efficacy of Phosphodiesterase Type 5 Inhibitor Treatment in Men with Erectile Dysfunction and Dyslipidemia: A Post Hoc Analysis of the Vardenafil Statin Study. J Sex Med. Feb Eardley I, Lee JC, Shabsigh R, et al. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. J Sex Med. Jan;7(1 Pt 1): Weiss RJ. Effects of antihypertensive agents on sexual function. Am Fam Physician Dec;44(6): McLaughlin T, Harnett J, Burhani S, Scott B. Evaluation of erectile dysfunction therapy in patients previously nonadherent to long-term medications: a retrospective analysis of prescription claims. Am J Ther Nov Dec;12(6): Macdonald S, Halliday J, Mac ET, et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case-control study. Br J Psychiatry Jan;182: Aizenberg D, Modai I, Landa A, Gil-Ad I, Weizman A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry Jul; 62(7): Gopalakrishnan R, Jacob KS, Kuruvilla A, Vasantharaj B, John JK. Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry Mar;163(3): Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10(3): Mitsonis CI, Mitropoulos PA, Dimopoulos NP, et al. Vardenafil in the treatment of erectile dysfunction in outpatients with chronic schizophrenia: a flexible-dose, open-label study. J Clin Psychiatry Feb;69(2): Data on file. US Food and Drug Administration Website. Available at: Accessed 2009 Jan Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology Nov;64(5): ; discussion Data on file. US Food and Drug Administration Website. Available at: Accessed 2009 Jan Rubio-Aurioles E, Porst H, Eardley I, Goldstein I. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med Nov;3(6): Jannini EA, Isidori AM, Gravina GL, et al. The ENDTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med Sep;6(9): Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol ct;170(4 Pt 1): McCullough AR. Rehabilitation of erectile function following radical prostatectomy. Asian J Androl Jan;10(1): Leungwattanakij S, Bivalacqua TJ, Usta MF, et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl Mar Apr;24(2): Montorsi F, Guazzoni G, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol ct;158(4): Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology Aug;68(2): Clinical Medicine Insights: Therapeutics 2010:2

11 Vardenafil 42. Zhang R, Wang Y, Zhang L, et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke Nov; 33(11): Foresta C, Caretta N, Lana A, et al. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. Eur Urol May;51(5):1411 7; discussion De Young LX, Domes T, Lim K, Carson J, Brock GB. Endothelial Rehabilitation: The Impact of Chronic PDE5 Inhibitors on Erectile Function and Protein Alterations in Cavernous Tissue of Diabetic Rats. Eur Urol Jul;54(1): Padma-Nathan H, McCullough A, Forest C. Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Curr Urol Rep Dec;5(6): Montorsi F, Brock G, Lee J, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nervesparing radical prostatectomy. Eur Urol ct;54(4): Publish with Libertas Academica and every scientist working in your field can read your article I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely. The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I ve never had such complete communication with a journal. LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought. Your paper will be: Available to your entire community free of charge Fairly and quickly peer reviewed Yours! You retain copyright Clinical Medicine Insights: Therapeutics 2010:2 975

IC351 (tadalafil, Cialis): update on clinical experience

IC351 (tadalafil, Cialis): update on clinical experience (2002) 14, Suppl 1, S57 S64 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir IC351 (tadalafil, Cialis): update on clinical experience 1 * 1 Urological practice,

More information

Review Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution

Review Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution Advances in Urology Volume 2009, Article ID 852437, 4 pages doi:10.1155/2009/852437 Review Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution

More information

Opinion: Yes. PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation?

Opinion: Yes. PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? Difference of opinion Vol. 43 (3): 385-389, May - June, 2017 doi: 10.1590/S1677-5538.IBJU.2017.03.03 PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? Opinion:

More information

for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology

for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology Tadalafil 5 mg once daily for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology Why this conference? Not promotional but educational The pharmacist regularly

More information

/02/ /0 Vol. 168, , October 2002 THE JOURNAL OF UROLOGY

/02/ /0 Vol. 168, , October 2002 THE JOURNAL OF UROLOGY 0022-5347/02/1684-1332/0 Vol. 168, 1332 1336, October 2002 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2002 by AMERICAN UROLOGICAL ASSOCIATION, INC. DOI: 10.1097/01.ju.0000028041.27703.da Original

More information

A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction

A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction Anthony J. Bella MD, FRCSC Division of Urology, Department of Surgery and Department of Neuroscience

More information

The efficacy and safety of tadalafil: an update

The efficacy and safety of tadalafil: an update Original Article C.C. CARSON et al. The efficacy and safety of tadalafil: an update C.C. CARSON, J. RAJFER, I. EARDLEY, S. CARRIER, J.S. DENNE, D.J. WALKER, W. SHEN and W.H. CORDELL Department of Surgery,

More information

Medicines Q&As. Date prepared: November 2016

Medicines Q&As. Date prepared: November 2016 Q&A 128.3 What is the rationale and evidence for the use of phosphodiesterase-5 inhibitors as supportive therapy to rehabilitate Erectile Function after nerve sparing radical prostatectomy? Summary Prepared

More information

MALE SEXUAL DYSFUNCTION. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara

MALE SEXUAL DYSFUNCTION. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara MALE SEXUAL DYSFUNCTION Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara DEFINITION The inability to achieve a satisfactory sexual relationship May involve : - inadequacy

More information

Managing Erectile Dysfunction

Managing Erectile Dysfunction Managing Erectile Dysfunction Lewis E. Harpster MD, FACS Urology of Central PA 4/23/16 1 Objectives 1. Review physiologic mechanism of erection 2. Discuss medical management of ED 3. Discuss surgical management

More information

MANAGEMENT UPDATE , LLC MedReviews

MANAGEMENT UPDATE , LLC MedReviews MANAGEMENT UPDATE 2013 MedReviews, LLC rostate cancer is the most common cancer in men over the age of 50 years. 1 When patients undergo a radical prostatectomy (RP), there is a risk of postoperative erectile

More information

Defined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several

Defined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several Defined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several months and occurring at least half the time. Vinik

More information

MMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS

MMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established

More information

Erectile Dysfunction: A Primer for Primary Care Providers

Erectile Dysfunction: A Primer for Primary Care Providers Erectile Dysfunction: A Primer for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the definition, incidence and prevalence of Erectile Dysfunction in the U.S. 2. Understand

More information

Evidence Review for Surrey Prescribing Clinical Network. Treatment: Oral and non-oral combination therapy for erectile dysfunction

Evidence Review for Surrey Prescribing Clinical Network. Treatment: Oral and non-oral combination therapy for erectile dysfunction Evidence Review for Surrey Prescribing Clinical Network Treatment: Oral and non-oral combination therapy for erectile dysfunction Prepared by: Linda Honey Topic Submitted by: Prescribing Clinical Network

More information

ERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION. Gregory Harochaw Pharmacy Manager Tache Pharmacy (204)

ERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION. Gregory Harochaw Pharmacy Manager Tache Pharmacy (204) ERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION Gregory Harochaw Pharmacy Manager Tache Pharmacy (204) 233-3469 Nerve Function After careful prostatectomy where the erectile

More information

GUIDELINES ON ERECTILE DYSFUNCTION

GUIDELINES ON ERECTILE DYSFUNCTION 16 GUIDELINES ON ERECTILE DYSFUNCTION E. Wespes (chairman), E. Amar, D. Hatzichristou, Dr. F. Montorsi, J. Pryor, Y. Vardi Eur Urol 2002;41:1-5 1. Background, definition and classification Male erectile

More information

Penile Rehabilitation After Radical Prostatectomy: Important Therapy or Wishful Thinking?

Penile Rehabilitation After Radical Prostatectomy: Important Therapy or Wishful Thinking? MANAGEMENT UPDATE Penile Rehabilitation After Radical Prostatectomy: Important Therapy or Wishful Thinking? Joseph E. Dall Era, MD, Jesse N. Mills, MD, Hari K. Koul, MD, Randall B. Meacham, MD Division

More information

Penile Rehabilitation after Radical Prostatectomy

Penile Rehabilitation after Radical Prostatectomy Penile Rehabilitation after Radical Prostatectomy The PRO Position John P. Mulhall MD MSc FECSM FACS Director, Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center

More information

Sidney Glina Faculdade de Medicina do ABC Instituto H. Ellis Editor-in-Chief of the International Brazilian Journal of Urology

Sidney Glina Faculdade de Medicina do ABC Instituto H. Ellis Editor-in-Chief of the International Brazilian Journal of Urology Sidney Glina Faculdade de Medicina do ABC Instituto H. Ellis Editor-in-Chief of the International Brazilian Journal of Urology (www.intbrazjurol.com.br) glinas@terra.com.br Conflict of Interest: In the

More information

ERECTILE DYSFUNCTION DIAGNOSIS

ERECTILE DYSFUNCTION DIAGNOSIS ERECTILE DYSFUNCTION DIAGNOSIS Head of Andrology and Sexual Medicine Dep.of Urology and Nefrology Hospital Virgen del Rocío ANDROMEDI. Sexual Medicine SEVILLA. SPAIN General Secretary ESSM Natalio Cruz

More information

Testosterone and PDE5 inhibitors in the aging male

Testosterone and PDE5 inhibitors in the aging male Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005

More information

Sponsored by. Schering. Sidney Glina

Sponsored by. Schering. Sidney Glina Sponsored by Schering Sidney Glina Testosterone and erectile dysfunction Sidney Glina Keywords Androgen Hormone replacement therapy Hypogonadism Impotence Testosterone Abstract The role of testosterone

More information

Daily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer

Daily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer Daily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) February 2018

More information

Review Article Overview of Contemporary Penile Rehabilitation Therapies

Review Article Overview of Contemporary Penile Rehabilitation Therapies Hindawi Publishing Corporation Advances in Urology Volume 2008, Article ID 481218, 6 pages doi:10.1155/2008/481218 Review Article Overview of Contemporary Penile Rehabilitation Therapies Peter Hinh and

More information

Gerald Brock Professor of Surgery University of Western Ontario

Gerald Brock Professor of Surgery University of Western Ontario Treatment Induced Erectile Dysfunction Gerald Brock Professor of Surgery University of Western Ontario 1 1 2 Should you believe in Rehab? 3 3 Should you believe in Rehab? Avoidance Education related to

More information

Schemi terapeutici complessi per la gestione della disfunzione erettile post trattamento del carcinoma prostatico: non solo PDE5i

Schemi terapeutici complessi per la gestione della disfunzione erettile post trattamento del carcinoma prostatico: non solo PDE5i Schemi terapeutici complessi per la gestione della disfunzione erettile post trattamento del carcinoma prostatico: non solo PDE5i M. Lazzeri MD-PhD Department of Urology Ist. Clinico Humanitas IRCCS Schema

More information

Managing the Patient with Erectile Dysfunction: What Would You Do?

Managing the Patient with Erectile Dysfunction: What Would You Do? Managing the Patient with Erectile Dysfunction: What Would You Do? Florida A & M University College of Pharmacy and Pharmaceutical Sciences 42 nd Annual Clinical Symposium Wayne A. Sampson, M.D. Cross

More information

Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil

Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil Sexual Medicine RECOVERY OF ERECTILE FUNCTION AFTER NERVE-SPARING RP WITH NIGHTLY LOW-DOSE SILDENAFIL BANNOWSKY et al. Associate Editor Michael G. Wyllie Editorial Board Ian Eardley, UK Jean Fourcroy,

More information

Canadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction

Canadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction Canadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction Last reviewed July 2014 Objectives 1. Define erectile dysfunction 2. List and classify the risk factors for erectile dysfunction

More information

Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction

Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction Robert C. Eyre, MD, FACS Associate Clinical Professor of Surgery (Urology) Harvard Medical School Post-prostatectomy Incontinence

More information

Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders

Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders DOI: 10.1111/j.1745-7262.2007.00227.x www.asiaandro.com. Clinical Experience. Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders Shih-Tsung

More information

Erectile Dysfunction Medical Treatment

Erectile Dysfunction Medical Treatment 1 Erectile Dysfunction Medical Treatment Alireza Ghoreifi Assistant of Urology Mashhad University of Medical Sciences March 2012 2 Treatment of ED Unknown cases of ED First-line therapy Second-line therapy

More information

I N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E

I N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E I N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E 2 0 1 6 DESPITE THE COMMON COMPLAINT, EACH PATIENT COMES AS AN INDIVIDUAL, WITH UNIQUE EXPECTATIONS My special interest Counseling patients

More information

Up to 85 Percent of Men Achieved Significantly Improved Erections

Up to 85 Percent of Men Achieved Significantly Improved Erections Corporate Investor Relations First Release of Vardenafil Phase III Pivotal Study Data: Up to 85 Percent of Men Achieved Significantly Improved Erections Additional Phase III Data Show Significant Improvement

More information

Phosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary

Phosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary Phosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-4,23 Agent FDA Approved Dosage and Administration Indication Cialis (tadalafil) (ED) ED; As needed:

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE. Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE. Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2012 Review date: September 2014 Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy JPC Recommendation:

More information

GUIDELINES ON ERECTILE DYSFUNCTION

GUIDELINES ON ERECTILE DYSFUNCTION GUIDELINES ON ERECTILE DYSFUNCTION (Text updated March 2005) E. Wespes (chairman), E. Amar, D. Hatzichristou, K. Hatzimouratidis, F. Montorsi, J. Pryor, Y. Vardi 88 Erectile Dysfunction Eur Urol 2001;40:97-101

More information

Erectile dysfunction. By Anas Hindawi Supervised by Dr Khalid AL Sayyid

Erectile dysfunction. By Anas Hindawi Supervised by Dr Khalid AL Sayyid Erectile dysfunction By Anas Hindawi Supervised by Dr Khalid AL Sayyid ED is the persistent/recurrent inability to attain and/or maintain a penile erection rigid enough for satisfactory sexual intercourse

More information

Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction

Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction Ian Eardley, 1 Peter Ellis, 2 Mitradev Boolell 2 & Maria Wulff 2 1 Department of Urology, St James University

More information

Pharmacokinetics, Pharmacodynamics, and. Sussman Phosphodiesterase Type 5 Inhibitors

Pharmacokinetics, Pharmacodynamics, and. Sussman Phosphodiesterase Type 5 Inhibitors Clinical evidence in men with erectile dysfunction (ED) shows that the phosphodiesterase type 5 (PDE5) inhibitors sildenafil citrate, tadalafil, and vardenafil hydrochloride have favorable safety and efficacy

More information

Clinical Trial Study Synopsis

Clinical Trial Study Synopsis Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency

More information

Erectile Dysfunction Prior Authorization with Quantity Limit Criteria Program Summary

Erectile Dysfunction Prior Authorization with Quantity Limit Criteria Program Summary Prior Authorization with Quantity Limit Criteria Program Summary Objective The intent of the prior authorization (PA) program for (ED) is to ensure appropriate selection of patients for treatment according

More information

Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis

Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis (2003) 15, 318 322 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction

More information

Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) A Second Generation Technology

Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) A Second Generation Technology Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) A Second Generation Technology Y. Reisman, MD, PhD. 1, A. Hind, MD. 2, A. Varaneckas, MD. 3, I. Motil, MD. 4 1 Men's Health

More information

LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP

LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP ADULT UROLOGY LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP RUPESH RAINA, MILTON M. LAKIN, ASHOK AGARWAL, RAKESH SHARMA, KUSH K. GOYAL, DROGO

More information

Disclosure Slide. Dr Michael Gillman IMPOTENCE ERECTILE DIFFICULTIES. Do Men Really Care??? 15/10/2014 ASSESSMENT OF ERECTILE DYSFUNCTION

Disclosure Slide. Dr Michael Gillman IMPOTENCE ERECTILE DIFFICULTIES. Do Men Really Care??? 15/10/2014 ASSESSMENT OF ERECTILE DYSFUNCTION ASSESSMENT OF ERECTILE DYSFUNCTION Dr Michael Gillman St Andrews Hospital North St Specialist Suites Mater Hospital 3 rd Floor Mater Private Clinic Wesley Hospital Suite 5 Level 9 Evan Thomson Bld Cleveland-

More information

Clinical Trial Study Synopsis

Clinical Trial Study Synopsis Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency

More information

TITLE: Phosphodiesterase 5 Inhibitors: A Review of the Clinical Effectiveness and Cost- Effectiveness

TITLE: Phosphodiesterase 5 Inhibitors: A Review of the Clinical Effectiveness and Cost- Effectiveness TITLE: Phosphodiesterase 5 Inhibitors: A Review of the Clinical Effectiveness and Cost- Effectiveness DATE: 15 July 2010 CONTEXT AND POLICY ISSUES: Erectile dysfunction is the most commonly encountered

More information

Is This Really a Fair Debate? 2013 MFMER slide-2

Is This Really a Fair Debate? 2013 MFMER slide-2 Sex Rehab after Radical Prostatectomy: Is it Really Justified? Con Position Landon Trost, MD Assistant Professor of Urology Mayo Clinic, Rochester, MN ISSM 16 th World Meeting on Sexual Medicine October

More information

Tadalafil: a novel treatment for erectile dysfunction

Tadalafil: a novel treatment for erectile dysfunction European Heart Journal Supplements (22) 4 (Supplement H), H24 H31 Tadalafil: a novel treatment for erectile dysfunction F. Giuliano 1 and L. Varanese 2 1 Department of Urology, AP-HP, Centre Hospitalier

More information

Clinical Trial Study Synopsis

Clinical Trial Study Synopsis Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency

More information

Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction

Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction (2000) 12, Suppl 1, S75±S80 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of

More information

Erectile Dysfunction (ED) Shawn McGee M.D. CentraCare Adult and Pediatric Urology January 30 th, 2016

Erectile Dysfunction (ED) Shawn McGee M.D. CentraCare Adult and Pediatric Urology January 30 th, 2016 Erectile Dysfunction (ED) Shawn McGee M.D. CentraCare Adult and Pediatric Urology January 30 th, 2016 Erectile dysfunction: The inability to attain or maintain penile erection sufficient for satisfactory

More information

Erectile Dysfunction; It s Not Just About Sex

Erectile Dysfunction; It s Not Just About Sex Erectile Dysfunction; It s Not Just About Sex Disclosures Conflict of interest: I am not paid by Boston Scientific but once in a while they buy me a tasty meal. I do routinely use their products without

More information

Penile rehabilitation after radical prostatectomy: patients attitude and feasibility in China

Penile rehabilitation after radical prostatectomy: patients attitude and feasibility in China Original Article Penile rehabilitation after radical prostatectomy: patients attitude and feasibility in China Yi-Jun Shen 1,2, Jian Li 1,2, Ding-Wei Ye 1,2 1 Department of Urology, Fudan University Shanghai

More information

Abstract. Introduction. Vascular and cavernosal smooth muscle in the penis

Abstract. Introduction. Vascular and cavernosal smooth muscle in the penis RBMOnline - Vol 7. No 4. 456 461 Reproductive BioMedicine Online; www.rbmonline.com/article/994 on web 9 October 2003 Article Novel PDE5 inhibitors for the treatment of male erectile dysfunction Jas Kalsi

More information

Dipartimento Ostetricia, Ginecologia, Urologia - Clinica Urologica Università di Napoli Federico II, Italy; 2

Dipartimento Ostetricia, Ginecologia, Urologia - Clinica Urologica Università di Napoli Federico II, Italy; 2 ORIGINAL PAPER DOI: 10.4081/aiua.2016.2.128 A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil

More information

ORIGINAL ARTICLE Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care

ORIGINAL ARTICLE Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care (2007) 19, 393 397 & 2007 Nature Publishing Group All rights reserved 0955-9930/07 $30.00 www.nature.com/ijir ORIGINAL ARTICLE Post-marketing surveillance study of the efficacy and safety of vardenafil

More information

, David Stultz, MD. Erectile Dysfunction. David Stultz, MD September 10, 2001

, David Stultz, MD. Erectile Dysfunction. David Stultz, MD September 10, 2001 Erectile Dysfunction David Stultz, MD September 10, 2001 Case Presentation A 66 year old male presents to your office requesting Viagra. He states that for the past year he has had difficulty forming

More information

Erectile Dysfunction Case Study 2. Medical Student Case-Based Learning

Erectile Dysfunction Case Study 2. Medical Student Case-Based Learning Erectile Dysfunction Case Study 2 Medical Student Case-Based Learning The Case of Mr. Power s Limp Mojo Mr. Powers develops erectile dysfunction after his radical prostatectomy for prostate cancer. You

More information

ORIGINAL INVESTIGATION. Sildenafil for Male Erectile Dysfunction

ORIGINAL INVESTIGATION. Sildenafil for Male Erectile Dysfunction Sildenafil for Male Erectile Dysfunction A Systematic Review and Meta-analysis ORIGINAL INVESTIGATION Howard A. Fink, MD, MPH; Roderick Mac Donald, MS; Indulis R. Rutks, BS; David B. Nelson, PhD; Timothy

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright, 199, by the Massachusetts Medical Society VOLUME 33 M AY 14, 199 NUMBER ORAL IN THE TREATMENT OF ERECTILE DYSFUNCTION IRWIN GOLDSTEIN, M.D., TOM F. LUE, M.D.,

More information

Sexual Dysfunction Caused by Cancer Treatments Issues in Men. Dr Christopher Love

Sexual Dysfunction Caused by Cancer Treatments Issues in Men. Dr Christopher Love Sexual Dysfunction Caused by Cancer Treatments Issues in Men Dr Christopher Love Urological and Prosthetic Surgeon Bayside Urology 66 Balcombe Rd., Mentone Men s Health Melbourne Level M 233 Collins St.,

More information

With My Heart, Can or Should I Take Erectile Dysfunction Drugs?

With My Heart, Can or Should I Take Erectile Dysfunction Drugs? With My Heart, Can or Should I Take Erectile Dysfunction Drugs? Timothy R. Malinowski MD, FACC UMG Carolina Cardiology Consultants Greenville Health System Definition of Erectile Dysfunction 1992 NIH Consensus

More information

ORIGINAL ARTICLE. Vardenafil A new and effective treatment for erectile dysfunction

ORIGINAL ARTICLE. Vardenafil A new and effective treatment for erectile dysfunction ORIGINAL ARTICLE Vardenafil A new and effective treatment for erectile dysfunction Richard Casey MD FRCS Urology, Editor-in-Chief R Casey. Vardenafil A new and effective treatment for erectile dysfunction.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Effect of penile rehabilitation on erectile function after bilateral nerve-sparing robotic-assisted radical prostatectomy

Effect of penile rehabilitation on erectile function after bilateral nerve-sparing robotic-assisted radical prostatectomy original article Journal of Andrological Sciences 2010;17:17-22 Effect of penile rehabilitation on erectile function after bilateral nerve-sparing robotic-assisted radical prostatectomy G. Novara, V. Ficarra,

More information

Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents

Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents FORMULARY MANAGEMENT Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents HELEN ELOISE CAMPBELL, BS, PharmD ABSTRACT BACKGROUND: Significant advances in the pharmacologic treatment

More information

ED treatments: PDE5 inhibitors, injections and vacuum devices

ED treatments: PDE5 inhibitors, injections and vacuum devices ED treatments: PDE5 inhibitors, injections and vacuum devices Martin Steggall Clinical Nurse Specialist (Erectile Dysfunction and Premature Ejaculation) Barts Health NHS Trust; Associate Dean, Director

More information

High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction

High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction (2002) 14, 533 538 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction 1 * 1 Australian

More information

Unstable angina following intracavernous injection of alprostadil: a case study

Unstable angina following intracavernous injection of alprostadil: a case study 1 di 6 03/09/2013 21.59 BMJ Case Rep. 2009; 2009: bcr03.2009.1658. Published online 2009 June 3. doi: 10.1136/bcr.03.2009.1658 Unexpected outcome (positive or negative) including adverse drug reactions

More information

Initial experience with linear focused shockwave treatment for erectile dysfunction: a 6-month follow-up pilot study

Initial experience with linear focused shockwave treatment for erectile dysfunction: a 6-month follow-up pilot study International Journal of Impotence Research (2014), 1 5 2014 Macmillan Publishers Limited All rights reserved 0955-9930/14 www.nature.com/ijir ORIGINAL ARTICLE Initial experience with linear focused shockwave

More information

Jan Farrell. Nurse Consultant Urology Department of Urology Rotherham General Hospital NHS FT

Jan Farrell. Nurse Consultant Urology Department of Urology Rotherham General Hospital NHS FT Jan Farrell Nurse Consultant Urology Department of Urology Rotherham General Hospital NHS FT Aims of session To promote discussion / interaction Opportunity to discuss with peers Promote learning / share

More information

Information for Patients. Priapism. English

Information for Patients. Priapism. English Information for Patients Priapism English Table of contents What is priapism?... 3 What causes priapism?... 3 Diagnosing priapism... 3 Treating priapism... 4 Conservative, first- and second-line treatments...

More information

Intraoperative Identification and Monitoring of the Somatic Nerves Critical to Potency Preservation during da Vinci Prostatectomy

Intraoperative Identification and Monitoring of the Somatic Nerves Critical to Potency Preservation during da Vinci Prostatectomy Intraoperative Identification and Monitoring of the Somatic Nerves Critical to Potency Preservation during da Vinci Prostatectomy J. Rasmussen, J. Schneider Background Since Walsh and Donker first introduced

More information

Jan Farrell Nurse Consultant Urological Services Department of Urology Rotherham General Hospital NHS FT

Jan Farrell Nurse Consultant Urological Services Department of Urology Rotherham General Hospital NHS FT Jan Farrell Nurse Consultant Urological Services Department of Urology Rotherham General Hospital NHS FT Aims of session To promote discussion / interaction Opportunity to discuss with peers Promote learning

More information

13-Oct-15 ERECTILE DYSFUNCTION. Urology Subdepartement dr. Mintohardjo Naval Hospital dr. Isdiyanto Septiadi, Sp.U

13-Oct-15 ERECTILE DYSFUNCTION. Urology Subdepartement dr. Mintohardjo Naval Hospital dr. Isdiyanto Septiadi, Sp.U ERECTILE DYSFUNCTION Urology Subdepartement dr. Mintohardjo Naval Hospital dr. Isdiyanto Septiadi, Sp.U 1 2 3 So what is impotence or erectile dysfunction..? The persistent inability to achieve or maintain

More information

Efficacy of Sildenafil Citrate at 12 Hours after Dosing: Re-exploring thetherapeutic Window

Efficacy of Sildenafil Citrate at 12 Hours after Dosing: Re-exploring thetherapeutic Window European Urology European Urology 46 (2004) 357 361 Efficacy of Sildenafil Citrate at 12 Hours after Dosing: Re-exploring thetherapeutic Window Ignacio Moncada *, José Jara, David Subirá, Irene Castaño,

More information

Prospective analysis of penile length changes after radical prostatectomy

Prospective analysis of penile length changes after radical prostatectomy Prospective analysis of penile length changes after radical prostatectomy Boback M. Berookhim, Christian J. Nelson*, Brian Kunzel, John P. Mulhall and Joseph B. Narus Male Sexual and Reproductive Medicine

More information

/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY

/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY 0022-5347/04/1722-0658/0 Reprinted from Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000132389.97804.d7

More information

Assessment of Erectile and Ejaculatory Function after Penile Prosthesis Implantation

Assessment of Erectile and Ejaculatory Function after Penile Prosthesis Implantation www.kjurology.org DOI:.4/kju.2.5.3.22 Sexual Dysfunction/Infertility Assessment of Erectile and Ejaculatory Function after Penile Prosthesis Implantation Jang Ho Bae, Phil Hyun Song, Hyun Tae Kim, Ki Hak

More information

Low Energy Shockwaves for the Treatment of Erectile Dysfunction Y. Vardi, B. Appel, I Gruenwald

Low Energy Shockwaves for the Treatment of Erectile Dysfunction Y. Vardi, B. Appel, I Gruenwald Low Energy Shockwaves for the Treatment of Erectile Dysfunction Y. Vardi, B. Appel, I Gruenwald Neuro-Urology Unit, Rambam Medical Center & the Technion Faculty of Medicine Haifa, Israel 3 crucial questions

More information

ERECTILE DYSFUNCTION TREATMENTS

ERECTILE DYSFUNCTION TREATMENTS ERECTILE DYSFUNCTION TREATMENTS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage

More information

Erectile Dysfunction and the Prostate Cancer Patient

Erectile Dysfunction and the Prostate Cancer Patient BAUN & Prostate cancer UK Erectile Dysfunction Study Day Erectile Dysfunction and the Prostate Cancer Patient Lorraine Montgomery Specialist Nurse Practitioner Urology Queen Elizabeth Hospital Gateshead

More information

avanafil 50mg, 100mg, 200mg tablets (Spedra ) SMC No. (980/14) A. Menarini Farmaceutica Internazionale SRL.

avanafil 50mg, 100mg, 200mg tablets (Spedra ) SMC No. (980/14) A. Menarini Farmaceutica Internazionale SRL. avanafil 50mg, 100mg, 200mg tablets (Spedra ) SMC No. (980/14) A. Menarini Farmaceutica Internazionale SRL. 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

Immediate penile prosthesis insertion after failed T shunt and snake maneuver in patient with prolonged priapism

Immediate penile prosthesis insertion after failed T shunt and snake maneuver in patient with prolonged priapism Immediate penile prosthesis insertion after failed T shunt and snake maneuver in patient with prolonged priapism Evangelos Zacharakis PhD, FRCS, FECSM, FEAA Consultant Urological Surgeon St Peter s Anrology

More information

Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors?

Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors? DOI 10.1007/s00345-016-1899-y LETTER TO THE EDITOR Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors? Zi jun Zou 1 Zhi hong

More information

LONG-TERM INTRACAVERNOUS THERAPY RESPONDERS CAN POTENTIALLY SWITCH TO SILDENAFIL CITRATE AFTER RADICAL PROSTATECTOMY

LONG-TERM INTRACAVERNOUS THERAPY RESPONDERS CAN POTENTIALLY SWITCH TO SILDENAFIL CITRATE AFTER RADICAL PROSTATECTOMY ADULT UROLOGY LONG-TERM INTRACAVERNOUS THERAPY RESPONDERS CAN POTENTIALLY SWITCH TO SILDENAFIL CITRATE AFTER RADICAL PROSTATECTOMY RUPESH RAINA, MILTON M. LAKIN, ASHOK AGARWAL, SANDRA AUSMUNDSON, DROGO

More information

Preserved Postoperative Penile Size Correlates Well with Maintained Erectile Function after Bilateral Nerve-Sparing Radical Retropubic Prostatectomy

Preserved Postoperative Penile Size Correlates Well with Maintained Erectile Function after Bilateral Nerve-Sparing Radical Retropubic Prostatectomy european urology 52 (2007) 702 707 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Preserved Postoperative Penile Size Correlates Well with Maintained Erectile

More information

Introduction. Original Article: Clinical Investigation. Lu Sun, 1,3 Fang-Li Peng, 2 Zhi-Ling Yu, 1 Cai-Ling Liu 1 and Jun Chen 3.

Introduction. Original Article: Clinical Investigation. Lu Sun, 1,3 Fang-Li Peng, 2 Zhi-Ling Yu, 1 Cai-Ling Liu 1 and Jun Chen 3. bs_bs_banner International Journal of Urology (2014) 21, 1263 1267 doi: 10.1111/iju.12564 Original Article: Clinical Investigation Combined sildenafil with vacuum erection device therapy in the management

More information

Penile Implant Should be Offered Early

Penile Implant Should be Offered Early Penile Implant Should be Offered Early Landon Trost, MD Assistant Professor in Urology Mayo Clinic, Rochester, MN SMSNA AUA May 16 th, 2015 2013 MFMER slide-1 Clear Indications for Penile Implants Men

More information

Ian Eardley Department of Urology, Leeds Teaching Hospital Trust

Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Assessment of the man with ED Medical therapy for man with ED What to do when pills fail Sexual stimulus Neural pathways Neurotransmitter

More information

Diagnosis and management of sexual dysfunction. Dr Chris Simpson Consultant Psychiatrist

Diagnosis and management of sexual dysfunction. Dr Chris Simpson Consultant Psychiatrist Diagnosis and management of sexual dysfunction Dr Chris Simpson Consultant Psychiatrist What are we talking about? Male Erectile dysfunction Premature ejaculation Delayed ejaculation Sexual aversion Paraphilia

More information

Erectile dysfunction: unmet needs

Erectile dysfunction: unmet needs Erectile dysfunction: unmet needs Dimitris Hatzichristou Professor of Urology / Andrology Director, Center for Sexual and Reproductive Health Aristotle University of Thessaloniki, Greece The numbers MMAS

More information

PhosphodiesteraseType-5 Inhibitors: A Critical Comparative Analysis

PhosphodiesteraseType-5 Inhibitors: A Critical Comparative Analysis EAU Update Series 2 (2004) 56 63 PhosphodiesteraseType-5 Inhibitors: A Critical Comparative Analysis Hartmut Porst * Private Urological Practice, Neuer Jungfernstieg 6a, D-20354 Hamburg, Germany Abstract

More information

ERECTILE DYSFUNCTION. & Current Therapies. GP Conference, Rotorua 7-10 June 2012

ERECTILE DYSFUNCTION. & Current Therapies. GP Conference, Rotorua 7-10 June 2012 ERECTILE DYSFUNCTION & Current Therapies GP Conference, Rotorua 7-10 June 2012 Jan Burns & Annie Woodsford Jan: EN, RCpN, BHSc, RPN (USA),MHSc, Member of the Sexual Medicine Society Urology Nurse Specialist

More information

Sexual function in men is shaped by biochemical, psychological

Sexual function in men is shaped by biochemical, psychological REVIEW Vardenafil: The clinical trial experience Peter J Pommerville MD FRCSC PJ Pommerville. Vardenafil: The clinical trial experience. J Sex Reprod Med 2003;3(1):15-21. Vardenafil is a new phosphodiesterase

More information

The effect of sildenafil on electrostimulation-induced erection in the rat model

The effect of sildenafil on electrostimulation-induced erection in the rat model (2002) 14, 251 255 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir The effect of sildenafil on electrostimulation-induced erection in the rat model N Ueno 1,

More information

Clinic for urology, pediatric urology and andrology. Penile diseases. Dr. Arne Hauptmann

Clinic for urology, pediatric urology and andrology. Penile diseases. Dr. Arne Hauptmann Clinic for urology, pediatric urology and andrology JUSTUS- LIEBIG UNVERISTY GIESSEN Penile diseases Dr. Arne Hauptmann Clinic for urology, pediatric urology and andrology University Giessen und Marburg

More information